Billion to One CEO Ozan Atay said a head-to-head study detected 50% more actionable therapies, oncology test volumes were growing faster than 100% year over year, and prenatal could sustain about 20% growth.
BLLN · BillionToOne, Inc.
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Up next
Latest documents
Billion to One reported third-quarter revenue of $123.0 million, up 47% year-over-year, raised its 2026 revenue outlook to $460 million to $470 million, and will launch Northstar Clear on December 15th.
BillionToOne reported nine-month revenue growth of 63% for the nine months ended September 30, 2026, driven by 34% growth in delivered and billable tests to approximately 590,000 and a 22% increase in Overall ASP. Revenue increased $131.8 million.
BillionToOne reported third-quarter revenue of $123.0 million, up 47%, and raised full-year 2026 revenue guidance to $460.0 million to $470.0 million from $450.0 million to $465.0 million. Net income was $17.4 million, or $0.32 per diluted share.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q3 FY26 earnings call · Nov 4, 2026TL;DR. BillionToOne delivered 47% revenue growth, 25% test-volume growth, 18% ASP growth, 96% oncology revenue growth, a 71% gross margin, GAAP operating income of $11.0 million and $8.6 million of free cash flow, while raising guidance and validating Unity Fetal Risk Screen prospectively. Risks include higher operating expenses, anticipated mix-related cost-per-test pressure, modest initial Northstar Clear revenue in 2027, and uncertainty surrounding PAMA reimbursement changes.
- + Third-quarter revenue grew 47%, test volume increased 25%, and overall ASP rose 18% year-over-year. new
- + Oncology revenue grew 96% year-over-year to $17.1 million. new
- + Management raised 2026 revenue guidance to $460 million-$470 million, representing 51%-54% growth. new
- + Northstar Clear, a pan-cancer tissue-free MRD test, is scheduled to launch commercially on December 15, 2026. new
- + Northstar Response agreed with the tumor-informed assay on 94% of sequential pairs, and clinical records supported Response's findings in all four divergent cases. new
- − Operating expenses increased 56% year-over-year to $76.1 million as R&D and SG&A spending increased. new
- − Cost per test increased as oncology grew faster than prenatal, and management anticipates further mix-driven cost pressure. new
- − Northstar Clear's revenue contribution is expected to remain modest in 2027. new
- − PAMA reimbursement changes face implementation uncertainty, and the aneuploid code used by the company is expected to decrease. new
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | 42.17M | Six Months Ended June 30, 2026 | — |
| EBITDA | 20.27M | Six Months Ended June 30, 2026 | — |
| Free cash flow non-GAAP | 16.05M | Six Months Ended June 30, 2026 | — |
| Overall ASP | $551 | Three Months Ended June 30 | — |
| Overall ASP change | 21% | the three months ended June 30, 2026 filing | — |
| Overall Cost Per Test change | 3% | the three months ended June 30, 2026 filing | — |
| Total tests accessioned | 197,000 | Three Months Ended June 30 | — |
| Total tests delivered | 196,000 | the second quarter of 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Diagnostics & Research — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
BLLN
this stock
BillionToOne, Inc.
|
$4.66B | +19.1% | +100.0% | 101.4 | 6.2% |
|
TMO
Thermo Fisher Scientific Inc.
|
$254.47B | +18.5% | +14.5% | 36.2 | 1.3% |
|
DHR
Danaher Corp
|
$158.84B | -1.4% | +8.5% | 36.9 | 1.2% |
|
IDXX
Idexx Laboratories Inc
|
$54.38B | +2.0% | +10.4% | 46.5 | 3.0% |
|
A
Agilent Technologies, Inc.
|
$48.55B | +26.6% | +6.4% | 33.9 | 1.7% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 10, 2026
- This year
- 16
Billion to One CEO Ozan Atay said a head-to-head study detected 50% more actionable therapies, oncology test volumes were growing faster than 100% year over year, and prenatal could sustain about 20% growth.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| BLLN | -13.0% | -5.8% | -0.3% | -14.0% | +19.1% |
| SPY | -2.3% | -4.8% | -2.9% | -3.1% | +7.4% |
| vs SPY | -10.6% | -1.0% | +2.6% | -10.9% | +11.7% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.